IPO
Company Profile
Clinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
Founded 2017Cambridge, MassachusettsAPMD
Investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Apnimed FAQ
- Is Apnimed publicly traded?
- Yes. Apnimed trades under the ticker APMD.
- Who are Apnimed's investors?
- Apnimed's investors include Shionogi, Columbia Seligman Technology and Information Fund, Alpha Wave Global, Morningside Ventures, Columbia Management, NexPoint Asset Management, Sectoral Asset Management.
Coverage Timeline
newest first- Aug 3, 2026IPOConsumer IPOs Are Getting Crushed While Biotech Pops→
- Jul 31, 2026IPOApnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill$192M IPO→
- Jul 31, 2026IPOApnimed Prices Upsized IPO at $16, Raises $192M$192M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO for Sleep Apnea Pill$150M-$160M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO For First Sleep Apnea Pillup to $150M IPO→
- Jul 10, 2026IPOApnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill→
All Coverage
IPO
Consumer IPOs Are Getting Crushed While Biotech Pops
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
IPO$192M IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
Apnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.
IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
IPO$192M IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
Apnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.
IPO
Apnimed Launches $150M IPO for Sleep Apnea Pill
IPO$150M-$160M IPO
Apnimed Launches $150M IPO for Sleep Apnea Pill
Apnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.
IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
IPOup to $150M IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.